CommentLife and death in the cART era
References (5)
Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis
Lancet
(2000)Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies
Lancet
(2008)
There are more references available in the full text version of this article.
Cited by (27)
How I treat patients with HIV-related hematological malignancies using hematopoietic cell transplantation
2017, BloodCitation Excerpt :In pre-alloHCT counseling, the unlikelihood of a virological cure of HIV infection should be carefully discussed with patients. Despite the example of the “Berlin patient,” HIV remains an incurable source of significant morbidity and mortality for infected patients.11,70-72 The challenges of eliminating HIV are several-fold and include the need to eradicate the viral reservoir while protecting the patient from future infection/reinfection by providing them with immunological resistance to HIV.
CTLA-4<sup>+</sup>PD-1<sup>−</sup> Memory CD4<sup>+</sup> T Cells Critically Contribute to Viral Persistence in Antiretroviral Therapy-Suppressed, SIV-Infected Rhesus Macaques
2017, ImmunityCitation Excerpt :The ability of antiretroviral therapy (ART) to effectively suppress HIV-1 replication has dramatically reduced HIV morbidity and mortality (Bhaskaran et al., 2008; Cooper, 2008).
Coadministration of tenofovir decreased atazanavir plasma concentration after unilateral nephrectomy
2013, Journal of Infection and ChemotherapyEpidemiology and Clinical Outcomes of HIV Infection in South-Central China: A Retrospective Study From 2003 to 2018
2022, Frontiers in Public Health
Copyright © 2008 Elsevier Ltd. All rights reserved.